RFK Jr. Forces FDA to Revisit Ban on 12 High-Risk, Unproven Peptides

The FDA is being compelled to reconsider its 2023 ban on a dozen unproven peptides, substances the agency itself flagged as posing significant safety risks. This reversal of regulatory posture is not driven by new scientific data but by direct political pressure from Health Secretary Robert F. Kennedy Jr., a prominent anti-vaccine figure who has publicly endorsed these substances.

The agency has scheduled advisory committee meetings for July and February 2027 to discuss potentially lifting restrictions on these 12 specific peptides. These compounds, often marketed online with bold claims about anti-aging, appearance enhancement, and treating various conditions, are typically injected and sold without evidence of safety or efficacy. While FDA-approved peptide drugs like insulin exist, the substances in question fall into a gray market of unregulated and risky biohacks.

The move places the FDA in a precarious position, forcing its scientific advisors to debate the fate of high-risk products based on political influence rather than clinical evidence. It signals a potential shift in regulatory enforcement under new leadership and raises critical questions about the integrity of the drug approval process when confronted with pressure from a top health official who champions unproven therapies.